Möchten Sie immer auf dem neuesten Stand bleiben?

           3Q19 Galafold® (migalastat) Revenue of $48.8M  and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M ...

CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019...

New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years...

Analyst Day 2019 to Highlight Financial Outlook andRobust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold® (migalastat) Preliminary Unaudited Revenue of ~$48M+  and 1,000+...

Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients...

CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming...

CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell,...

           2Q19 Galafold® (migalastat) Revenue of $44.1M Represents Highest Quarterly Growth Since Launch Driven by Continued Strong Global Uptake  Reiterating FY19 Revenue Guidance of $160M-$180M ...

         First Oral Precision Medicine Approved for People Living with Fabry Disease with an Amenable Mutation in Argentina First Amicus Regulatory Approval in Latin America CRANBURY, N.J., and...

 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment...